Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Recommendation of “Moderate Buy” from Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th.

Insider Buying and Selling at Regulus Therapeutics

In other Regulus Therapeutics news, VP Christopher Ray Aker sold 38,547 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,569.22. Following the transaction, the vice president now directly owns 54,634 shares of the company’s stock, valued at approximately $68,838.84. The trade was a 41.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Crispina Calsada sold 38,716 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,782.16. Following the sale, the chief financial officer now directly owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. This trade represents a 43.36 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 223,998 shares of company stock valued at $282,237. 4.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning acquired a new position in shares of Regulus Therapeutics during the third quarter worth approximately $26,000. SG Americas Securities LLC bought a new stake in Regulus Therapeutics during the 3rd quarter valued at $33,000. Jane Street Group LLC acquired a new position in Regulus Therapeutics during the third quarter worth $46,000. JPMorgan Chase & Co. grew its holdings in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 52,059 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Up 0.9 %

Shares of NASDAQ:RGLS opened at $1.14 on Thursday. Regulus Therapeutics has a 12-month low of $0.83 and a 12-month high of $3.79. The business has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $1.51.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.